E488 | This Week in European Tech with Dan, Mads & Lomax

9 Jun 2025 · 58 min

Ask about this episode

Ask anything about it. ChatGPT or Claude reads this page and answers with the times it was said.

Connect VO and ask about every podcast you hear, including the moments you saved. Add to ChatGPT · Add to Claude

In short

EUVC Podcast Episode Summary

Episode Information

  • Title: E488 | This Week in European Tech with Dan, Mads & Lomax
  • Release Date: [Insert Date]
  • Hosts: Andreas Munk Holm, David Cruz e Silva, Dan, Mads, Lomax

Episode Overview In this episode, the co-hosts discuss significant macro and micro trends shaping European tech and venture capital. Key themes include Europe's fiscal advantages, the movement of IPOs from the UK to the US, strategic defense investments, the intersection of AI and capital markets, and innovations in biotech, particularly in psychedelics.

---

Key Topics Discussed

  1. Europe’s Fiscal Advantage
  2. Fiscal Position: The European Union (EU) enjoys a better fiscal position compared to the US, with lower debt levels and a fiscal deficit.
  3. Interest Rate Cuts: The European Central Bank (ECB) has lowered interest rates, suggesting a conducive environment for startup investments.
  4. Strategic Investments: There is potential for strategic investments in areas such as defense and energy, leveraged by Europe's fiscal headroom.
  1. IPO Trends
  2. UK vs. US IPOs: The UK is experiencing an exodus of IPOs to the US, with significantly fewer IPOs and capital raised in the UK market compared to the US.
  3. Capital Market Dynamics: The liquidity and coverage disparities between US and UK markets affect startup funding and growth prospects.
  4. Notable IPOs: Despite broader trends, three of the ten largest IPOs last year occurred in Europe.
  1. AI and Capital Markets
  2. AI's Impact on Law: The use of AI in legal contexts is raising concerns over copyright and the validity of cited cases.
  3. Future of AI in Finance: The hosts discuss the integration of AI within capital markets, highlighting both opportunities and challenges.
  1. UK Strategic Defense Review
  2. Increased Defense Spending: The UK government plans a £67 billion defense budget over the next decade, focusing on technology and cybersecurity.
  3. Opportunities for Startups: While established defense contractors dominate, there are emerging opportunities for tech startups in areas like drones and AI.
  1. Healthcare Innovations
  2. Liquid Biopsy Technology: The NHS is adopting liquid biopsy technology for cancer treatment, heralding a shift towards precision medicine that can improve patient outcomes and reduce costs.
  3. Broader Implications: The episode discusses the potential for this technology to be applied across various cancers, emphasizing its significance in the healthcare sector.
  1. Psychedelics and Mental Health
  2. Emerging Trends: The discussion covers the growing interest in psychedelics for mental health treatment and the implications of ongoing clinical trials.

---

Key Takeaways

  • Europe’s Fiscal Health: Europe’s superior fiscal position compared to the US may provide advantages for innovation and startup funding.
  • IPO Landscape Challenges: The UK’s IPO market is struggling, with a critical need for reforms to attract and retain capital.
  • Strategic Investments: The need for strategic defense investments is becoming more apparent in light of geopolitical tensions.
  • Healthcare Transformation: Innovations like liquid biopsies represent a major leap forward for effective cancer treatment and healthcare efficiency.
  • Mental Health Innovations: The increasing focus on psychedelics reflects shifting attitudes and potential breakthroughs in mental health treatment.

---

Conclusion This episode provides a comprehensive overview of the current landscape in European tech and venture capital, touching on crucial themes of fiscal policy, market dynamics, technological advancements, and healthcare innovations. The conversation underscores the importance of strategic investments and adaptation in a rapidly evolving global context.

Written by AI. May contain mistakes. Listen to the episode to check what was said.

Hear the part that matters, and keep it.Open this episode in VO. Double tap your headphones to save a moment as you listen.
Get VO free

Transcript

Automatic transcript. May contain errors.

0:00Welcome to Upside, where we dig into the real stories that live behind the headlines affecting European venture. Today it's Lomax, Mads and myself and we are talking about the ECB cutting interest rates. We're going to go into a bit of IPO talk there. It's a tale of two cities on the IPO front. Dig into that. We're also talking about AI copyright and usage and lawyers doing naughty things. And then we're going to tail it off with the UK Strategic Defence Review. Oh and a little bit of liquid biopsy news from the NHS.

0:37It's more than just an alliance. This is a union of values. Let's start acting. This show is not investment advice and the hosts of this episode may be invested in the funds and companies featured. We are going to go straight to the top and it's the ECB cutting rates. What does this mean for Europe? What does this mean for the UK and in the global context? So to set the scene, the European Central Bank has cut its interest rate for the eighth time in 12 months from 2.25 % to 2 % as it warned about continuing pressure on the eurozone from Trump's tariffs. What does this mean for us, startups investing?

1:16Mads, I'm going to kick off with you because I know you know all of the real juice. Well, you know, it's not only good news, but it's mainly good news. And if you've got it, flaunt it and present it in the best way you can. So let's do that. Let's put a positive spin on it, at least to begin with. The story here is that the ECB is cutting headline rates from two and a quarter percent to two percent, which is the eighth cut in 12 months. And that's good. You know, rates are coming down. I think kind of the wider story is that the EU has fiscal headroom and the US does not because Trump desperately wants rate cuts, but he can't get them.

1:59The reason he can't get them is twofold. One is that EU inflation is now sub 2 % and heading in the right direction. And US inflation is at 2.3 % and not really heading in the right direction. partly for all the reasons we know. He's got Trump, the Trump tariffs that are adding, you know, costs on imports that are pushing up inflation. But on the top of that, they are also running a terrible fiscal deficit. The U.S. federal deficit is close to 7 % of GDP. It's an astronomical figure. It's sort of a wartime figure in what should be peacetime. So this U.S. growth, you know, the U.S. debt, a fiscal deficit pushes up growth, of course.

2:41And that comes from fiscal stimulus, which is why the GDP is growing faster. But it also adds strain to the long-term outlook of the U.S. economy. And the debt of the U.S. is now 50 % higher than the EU average. The U.S. at 124 % versus EU at 81%. And this means that the EU is just in a better fiscal position. Now, you could say there's a trade-off. The U.S. is growing at 2.6%. The EU is up 1%. Would it be better to have the growth? And yes, that's back to the, it's not only good news story. But there's no doubt that you would not want to be at 124 % debt to GDP with a near 7 % deficit. And on top of that, what they're trying to do now with this quote unquote big, beautiful bill is to add a further lump of stimulus, $2 trillion to$3 trillion further to the debt levels over the next several years.

3:43As we've seen, Musk did not like that very much and has left government doors slamming. I don't know whether we're going to come back to that today, but there is a real scarcity in the US. Are you going to stay clear? I would love to. I just don't think we can go there. I think it's just... my wife was saying to me that but it almost feels like comedy it's we've almost gone into like the the the wives of hollywood or whatever these awful reality tv shows is i don't even know where to go maybe maybe a low max you might have some words on this but mad sorry but before we go there on parody yeah yeah i mean just before we go there just i mean touching a little bit on where i think the opportunity is because being in a better fiscal position means we have opportunity in Europe and in particular around investments.

4:34Now, I'm not suggesting that we should let rip and just completely abandon all fiscal discipline, but we're seeing around defense where there's a real willingness to invest in our strategic defense capability. We could not have done that as easily, especially powered by Germany, if the European Union's fiscal position had not been as strong. That's one thing. The second thing is we have world-class capabilities in manufacturing, and manufacturing like AI is energy dependent. We've got amazing energy technology. I mean, Europe is great at things like nuclear. So kind of my take is this is a chance to use some of that fiscal headroom to invest strategically in energy, to bring down the cost of energy, and to provide more energy to manufacturing and to the AI sector.

5:28And I think the EU rate cuts show that that headroom is there. So that's really kind of would be my suggestion here, is that we look at that in an aggressive and strategic way. What about the flow of capital, Mads? This is the one thing you could argue almost from both directions. Obviously, weakening of the euro, does that mean that we'll see more money going into privates, more riskier assets? Will the yields in the States mean that we'll see more flow of capital back from Europe into the States as interest rates drop? So I don't know quite how to see it in that context as from the flow of capital context.

6:08I think those chains have slightly longer connections. And I think capital is global. So the fact that Europe has lower rates does not mean that European startups will get more funding. It's the thing we all want to see, but I just don't think it happens that easily. I think it's much more around providing the opportunity to create the foundation for more successful industry and tech sectors. And that is football attractive funding and then we just have the pure sentiment here which is do you really want to be investing in the states right now with such volatility and with such a volatile leader correct correct the counterpoint is europe has sub one percent gdp growth do you want to invest in a low growth environment and the uk even less right and the uk was downgraded even further last week so i just i have there's so many opposing forces yeah i mean you know let's talk about ipos and the stock markets in a minute but you know us is pumping at the moment i understand the volatility point dan but where do you want to invest i don't know the us still pretty compelling proposition there but i think mads just just to pick up on what you're saying i think you're very optimistic in what you say which which is good um i think my job there are of course yeah well i I think we're supposed to be optimists and pessimists at the same time.

7:31But yeah, exactly. I think certainly optimists generally. They're both long-term indirect consequences of what you just described, the rate cutting. I do actually think if you move back to a sustained period of low interest rates, then there is a rotation into riskier assets. And there is more funding available for startups. But if you think about it, basically interest rates for a sustained period, decade plus, were almost below zero. and then went up to, in Europe, this has went up to 4%, now back down to 2%. So for that, if we're seeing a sort of secular change or a shift back to a decade of very low interest rates, then I think on a five to 10-year lens, it is actually, it bodes well for European, for investments into riskier assets, which includes startups.

8:16I think on the investment into the critical things that you talk about, yeah, I mean, it's absolutely needed. We're going to, I think, talk about a day to 10 a little bit today, and the energy costs are an absolute abomination in europe and they need they need investment and it's it's great all of this just takes a very very long time but you know the governments with germany's big infrastructure spending bill and europe uk has got its um you know spending review coming out this week all those kind of investments are going to be necessary for for upgrading the infrastructure which will also unlock potentially you know significantly ai going forwards the us okay it's volatile there's a whole bunch of stuff going on across private and public markets.

8:57But just looking at the IPO piece of the picture, I mean, looking at the States versus the UK, it is absolutely two different stories. So US activity is about 80 % up on 2024 figures. And UK is nearly the same percentage, but in the wrong direction, with loads of green shoots happening in Europe. And here's a quick fun fact for you. Three out of 10 of the biggest IPOs of last year were in Europe. So that was Puig, the fashion and beauty brand on the Spanish exchange, Galderma, the dermatology company on the Swiss exchange, and CVC Cap, the PE firm who listed in Amsterdam. But Lomax, tell us more what's happening in IPO land.

9:37It really is kind of massive, massive stuff over there. Nafal over here. And then let's bring it back to how this affects our ecosystem, how this affects startups and investing. Well, I think there's a big headline grabbing numbers in the US and lots of walls of money moving, both being raised and being made for equity investors and pretty slim pickings in Europe. I mean, looking at some of the numbers, right? So if you take the US has done 143 IPOs this year. Take the UK, for example, has done five. And then one number that was really shocking to me is in the IPOs in the London market this year, only 75 million, total 75 million has been raised, right?

10:17Raised in fresh capital. whereas that number is about 13 billion in the US. It's quite depressing. I think this year there have been, I think no venture backed IPOs in London. In the US there's been nine. So significant ones we've seen. Hinge Health, CoreWeave, Armada, Circle Internet. You know, they had the choppy times earlier this year with Planner and StubHub postponing their IPOs but it seems to be back now. CoreWeave, one of Mads' favorite companies, has soared since IPO. It's up, you know, three times now, listed at$40, now$150. But it took a recent dip there, didn't it? I saw a recent dip.

10:52Gangbusters. Yeah, I know. It's up over 3x from IPO. Armada was up significantly up 50 % on its first day. Armada Health just IPO'd another tech-backed venture company. Or venture-backed tech company. So I think the story on the IPO scene is definitely very, very different. I think then couple that to some recent news where two UK listed companies have announced big changes in their listing. So Wise, which is the challenger bank, has just announced that it's moving its primary listing to the US. And Indivior, which is a pharma company, it was already primarily listed in the US, but it's cancelling its secondary listing in the UK.

11:38right so those two kind of big hits to the to the uk stock market in the um uh in the last week and i think why does this why does this happen well there's just much more money in the us right so it's easier to raise money there's significantly more analyst coverage one thing you can do just as a reminder is you can list in europe or list in the uk and you can still tap the us markets right so you can still have these things called american depository receipts if you're a european or UK company, but they are less liquid, less easy to raise money, as they don't have the analyst coverage and don't enable you to get into the relevant indices, S &P 500, et cetera.

12:14So it is very much a kind of secondary access to that capital market. And let's just step back. The US public capital markets, I think, is 50 trillion. And the UK is 3 trillion. So sometimes we think in venture that we talk about UK to US disparate, the difference is five to six, seven to eight times. The US is 17 times bigger when it comes to the size of the capital markets. And there's a really astonishing one, which is liquidity. US turnover per day is 500 billion of stock, 500 billion per day. In the UK, it's about eight to 10 billion per day. It's 50 times different. It's astonishing. So I think if you're wise and you're looking to raise more money, raise your profile in the US if you've got to go to market there as well, I think this is a bit of a no-brainer.

13:07It's just walking into a wall of money and exposure and profile, et cetera. I think the individual thing is a little bit secondary. They have most of their shareholders are in the US, most of their businesses in the US, all they're doing is canceling their secondary listing in the UK. Why is this relevant to tech and startups, guys? Because I think everything that happens in the public markets flows back to what we do. Ultimately, we are investing in early stage startups. Where are they going? They are going to the public markets and or private markets are valued by reference often to what's going on in the public markets.

13:40So it's incredibly important, both in terms of what's happening, the valuations there, that all flows back to what we do. Because ultimately, what are we doing? We're investing in startups and building companies that can become big standalone technology companies, which ultimately would be listed on one of these markets, right? And I'll just say one final point. In the UK, technology is 1 % of the FTSE 100. In the US, technology is 30 % of S &P. So when you think about it in the relevance of us and where our founders might want to go to IPO in the same light as Spotify, UiPath, Auto One out of Europe, the difference is...

14:24I think when we talk about US-EU difference a lot, it's this public capital markets piece that is staggering, I think, about the difference. The good news, really, of being an optimist, is, as Mad says, capital is global. It's not certainly not frictionless, but it's boundless. So you can take your European company, you can build hundreds of millions of revenue here, and there's a market for it in the US. So I think it's depressing that these companies aren't IPO-ing here and giving, enabling, for example, European pensioners to invest in these companies so much. But it's not the end of the world.

15:02I want to have a very quick sidebar conversation around Pisces. Not really on topic, but it just came to mind as you were speaking, Lomax. Now, Pisces, I can't remember what the acronym stands for, but it's a way effectively of getting stock options. and I guess it would be series BC startups or later stage startups to get more liquidity for founders and for stock options holders. So getting private markets, some version of a public market trading facility. But do either of you know any more about it? Will it be relevant at all? Will it work? I don't know if anyone knows anything on the Pisces topic.

15:46I think it's coming, it's now June. I think it's coming live in June. Really what Pisces and other schemes like it are trying to address is the symptom of a stock market where it is difficult to go public. Companies stay private for longer, but we still want to have liquidity and get people access to trade these underlying companies. And so we create these quasi-public markets or liquid markets or try to do that in private companies. and it just seems to me to be absolutely the wrong remedy and prescription for the symptom. Because public markets have their strength and private markets have their strength.

16:27And private markets are all about inside information, knowing the company closely, and being able to make quick decisions based on working closely with management teams and having that very intimate knowledge. That obviously does not work in a public market. You have insider trading laws, and people need to be able to trade on the basis of an equal access to information. And so the response to the public markets not working can't be to try and make public markets out of private markets. It's just bound to fail. It cannot work. Well, you can't raise fresh liquidity. I mean, you can't raise new capital using the Pisces scheme, can you?

17:07No, but you can still trade. You can trade. You talked about Carter, for example, trying to do this, like trying to create some little sister or little brother of what is a very well-established, highly regulated, centuries-old system. I'm sorry. I'm all for like optimism and new things and whatever. I don't think it works. And then, well, Carter pulled out of it. It's the thing you do with optimism. It's just a fundamental misunderstanding of how the markets are meant to work. The people that sell, by definition, are insiders. They're holding something. They're closer to it. and the buyers are outsiders.

17:40It's just, it's totally the wrong remedy. It's just, I was just wondering if there was any leaning in from this new scheme into the IPO discussion. I knew it was always going to be a bit of a sidebar. Yeah, I mean, so let's look back around the real story here, which is London's systematic failure as a public market. Endless delistings, very, very few new listings. You know, we talk about how much bigger the public stock markets are in the US than in the UK. And Lomax, you shared some great stats there. But one stat that is staggering is that you think about the US market as 16 to 17 times the size of the UK market today.

18:25But that's a new phenomenon. Yeah. If you go back 15 years or go back to 2007 before the great financial crisis, the S &P 500 was only about three times the size of the London Authority Exchange. So there's been a dramatic hollowing out of London's position as a financial center, especially on the equity side. Now, part of that is due to the weakening of the sterling. Sterling is down about 40 % over the period, but it just doesn't explain the whole difference. And so there are all these things. Lomax, you mentioned about liquidity crisis, you have much less daily turnover in the UK. You have a regulatory burden, which makes it hard to list.

19:08And I think to some extent, the whys and kind of move and the Circle IPO are perfect in yet, sir. Because if you go back 50 years, London was the go-to hub for fintech companies. And in so many ways, Circle is an example of a company that could have been and should have been built here, but was built in the US instead. And wise of a company that was built here and is here, but now is willing to listen to the US. There are missed opportunities all around. And just double clicking on what's happening here with crypto and stablecoins. So stablecoins are really becoming part of the global financial infrastructure.

19:49And we've seen with the new US Genius Act that's going through committee currently and kind of the role stablecoins are taking, today, Stripe is offering stablecoin accounts across more than 100 countries. So this is not about Crypto Ponzi, Lala. This is about using stablecoins as an alternative to traditional FX rails like Swift. And stablecoins have got a huge volume. I think the volume now is as much as Visa is processing on an annual basis globally. It's become a real thing, and we should have that here, but we've been fiddling, and the U.S. is capturing some of that. So we can go on to what can be done.

20:32I think it's clear that we need to strengthen the financial markets. I think so much of that, of course, is regulatory, multiple share classes, dual share classes for founder control. simplifying regulatory issues, but we also have to talk about money. And the truth is, 25 years ago, UK pension funds had 50 % of their assets in UK equities. And today it's less than five. You know, some of that people are saying is driven by a lack of tech companies in the UK. And yeah, that's fair. We need more. And some of that is driven by the fact that you have the global tech leaders and they're in the US and they're driving indices.

21:13and if you want to follow index performance, you have to be in these behemoth companies and so capital shifts to the US, right? And that's fine. I'm not proposing that we should stop that. But we're sitting in a death spiral here. When you go from 50 % to 5%, that is beyond the alarm bells. That's like, this is near terminal. And I think it's an excellent example of why we need pension reform. Now, I think this should cover both public and private markets. On the private market side, we've talked about how difficult it is for pension funds in Europe to invest in venture capital and private assets.

21:52And there is a long list of reasons, kind of their fee caps, their some of the fiduciary rules around what trustees needs to do and kind of not giving them a safe harbor provision that could protect them. And there's also scale fragmentation, but too many small schemes. All of that can be addressed. But I think coming back to the public markets discussion, I think there's a wider point here, which is that today the UK gives very, very generous tax incentives for pension savings. So it costs more than 50 billion pounds a year. It's equivalent to almost 5%, 4.5 % of all public spending is the equivalent of the tax incentives that go to pension savings.

22:39That's the same as the defense budget, basically, yeah. Right? And so I don't think it's unreasonable to say that in exchange for these very generous tax breaks, that some of the funds have to be put to use to invest in productive assets in the UK, both in public and private. And so I think there's a huge opportunity here. I mean, it's going to take some political will. And I do think the government has sight of some of this. But again, we just need to move a little bit more decisively. we're into overtime here and it feels like we're taking our sweet time working this but you know what mads you know you know sorry just to jump in i from memory there's there's roughly i think three trillion of assets in combined in uk pension right i think across the defined benefit and contribution schemes so even if you increase the allocation of those you know that three trillion of assets, you enforce a rotation out of the US into the UK, still not really moving the needle massively.

23:44But I guess, you know, in the context of, yeah, I guess in the context of London, which we just said has roughly three trillion of market cap total, right? So you could potentially move that significantly. But in the context of the US is 50 trillion of market cap, you're not even And you're not really helping the UK. I mean, you're helping it, but you're not bridging the gap in any meaningful way at all, right? There are two things out there. There is market cap, which is kind of the value of the total market. And then there's money that's put into a market. I think part of the argument I would make here is that the value of a company is often determined on the marginal supply and demand.

24:30not the total supply and demand. So we don't have to put 3 billion pounds more into UK equity to increase the value of UK equities by 3 billion pounds. Okay, just by having more marginal demand, you can increase the multiples, and that will increase the total value. But that's one point. The second point is we need more capital across not just Publix, but the full stack. So we create more IPO candidates. and that's especially around growth it's kind of the pre-ipo phase whereas if all the great tech companies go to the uk and list well then obviously the uk to raise their growth round they're also going to list in the uk and if we can put more capital to use in the later venture phases here i definitely think that will help the ipo funnel it's all about more money i want to change tack i want to just dip into a couple of ai stories that have cropped up this week so one being the creative industries have according to Baroness Beban Kidron of Bridget Jones fame she was the director of one of the Bridget Jones movies so she's in the Lords and and she has basically said that the creative industries are being shafted by the UK government so the UK government is trying to pass a bill that will allow AI companies to use copyright material with an opt-out and the Lords has rejected this proposal for the fourth time and the second story that I wanted to dig into and I'll tell you why in a second was that lawyers are now facing sanctions if they cite cases after using chat GPT that don't actually exist.

26:03There have been a number of high profile cases of lawyers using citing cases that don't exist in the real world. So AI is now obviously butting heads in the real world and there'll be much more to come. What sector is next? Who will the winners and losers be? There are so many questions around this kind of where AI meets the real world. You know, to be honest, I don't have a strong opinion where this is going to go. You know, there's this new data use and access bill that's been battered back and forth between the House of Commons and the House of Lords in the UK. I think the Lords have sent it back three times.

26:36The Commons can push it through anyway, so it's largely academic, quite frankly. I think the major sticking point now is it's not the concept of the AI companies being able to use copyrighted material, but it's around disclosure. I think the Lords really wants to force the AI companies to actually disclose where they've used copyrighted material. I mean, okay, fine. I mean, I don't have a strong opinion where that ends up. Hasn't the horse already bolted? Hasn't the internet already been absorbed? Yeah, okay. I wouldn't necessarily take, I mean, I think if there was, look, I mean, this is a big industry.

27:11Take the UK, but it will apply across other economies too. This is roughly contributing. The creative industries contribute roughly all, you know, the size of them is roughly 135 billion pounds in the UK. So these are not insignificant parts of the economy. And I think just to not protect them and let them go up in flames is clearly, which, by the way, is not going to happen. I think that's hyperbole. Is there a way in which, you know, compensation can be managed? I think it would need to be a commercial thing rather than like a regulatory thing. I don't know. I don't know, Mads, if you have a strong view here, but I'm just, I don't know where this ends up, quite frankly.

27:49Like in the US, it's a little bit more permissive. They have this concept of fair use when you're using copyrighted material. And as always, as you would expect in the UK and the EU, it's more restrictive. I don't think the government should be mandating payments. I wonder where I would love it if there was a way for the creators to make money out of this. And to be honest, the commercially savvy ones will probably find a way to do that. The tension, right? The tension is between the freedoms around AI and the economic boon therein and protecting copyright holders. That's the tense piece. But Mads, where would you take this?

28:28Yeah, going one step further in the context of what we've just talked about, creating more great technology companies in Europe and in the UK, if you have competitors where in China you have, should you say, a very relaxed interpretation of Western IP protection laws. And in the US, actually, people talk a lot about the US fair use, but there are a lot of lawsuits now underway. But you have an environment where you have a lot more capital. And so the large AI companies can count on A, massive war chests, and B, almost infinite investor backing to weather. Isn't Reddit suing Anthropic? Who's suing Anthropic?

29:12Yes, Reddit is. But Anthropic can go into this knowing that they can raise probably as many billions as they need at the end of the day. It will be litigated in the US, and a solution will be found. And that's just a really cut path. Well, and also, by the way, Reddit and their lawyers will know that, right? So in a way, it's all just part of the kind of US, like the very, very commercial way they approach litigation in that jurisdiction. There is that. But we also need to think about it from the perspective of investors, because our investors are going to fund that business model in Europe, knowing that there's much less capital available.

Read the full transcript

29:47And so there is a real tension there. I think the question is, how do you find a middle ground? Of course, we want to protect these wonderful creatives that have given us so many amazing enjoyments and cultural treasures over the years. And at the same time, we don't want to fall behind on AI. And I think, you know, what are some of the things that can be done? I mean, you can look at opt-outs rather than opt-ins. So saying that, yes, there is a general blanket permission to train unless people have specifically opted out. you can provide safe harbor provisions for open source technologies or for smaller projects to make sure that if you are sub 25 or 50 million in revenue basically there is no or you have a safe harbor circle around you you can't be sued or if you are then you you can sort of claim safe harbor so there i think there are a lot of things that can be done to stimulate the environment but it's clear there's a tension i think we can't shy away from that i always wonder if there'll be a commercial model around working out which model has absorbed which copyright material and then working out some kind of spotify-esque apportionment but i don't know i mean on a practical level if a song is created by ai and it's inspired by stevie wonder and george michael and michael jacks i don't know how you would i don't know how you would work out how many beats in the bar of or apportioned or how many pixels in the picture report.

31:12It's just such a quagmire. I would not like to be on any sides of this coin. Changing tack even further, we're bouncing around a lot today, but we've had the UK Strategic Defence Review out. So this is a NATO first plan to bring the UK up to speed to protect itself and other NATO countries, spending around 87 billion over the next 10 years. How much is to be spent on what, where, are there opportunities for startups, investors or not? Interestingly, the government may force slash encourage the use of UK vendors. Currently looks like there's about 60 % of the existing spend will be spent in the UK by the UK, which is great to see.

31:53But with 80 % plus spent on physical things, including kinetics, boats, submarines and around a billion to be spent on digital and cyber. Is that the right proportion? can we even afford any of this? Lomax, give us some more of the juice on what's happening with the UK strategic defensive spend. Well, we talked a lot about defence on this pod before, both UK, US and Europe. I think this is the latest strategic defence review by the UK. It's the first one since the Russian invasion of Ukraine, at least the 2022 version, not the 2014 version. I think it's no doubt a good thing that the UK, well, given the geopolitical environments at the moment, And it's not surprising that the UK is now increasing defense spending.

32:34I mean, the numbers are still relatively small, actually. You know, like we're talking about increasing defense spending. So from 2.3 to 2.5 % of GDP, with a longer term goal of 3%. I mean, that does put it above the 2 % NATO target, still below the likes of, at least in percentage terms, Poland, Estonia, Latvia, which are 4%. But it's still, in absolute terms, the sixth biggest defense budget in the world. still significantly smaller than the US, which is close to a billion dollars. We're now, you know, roughly a hundred, sorry, a trillion dollars. And this will, this spending review will take us to roughly a hundred billion dollars.

33:10So 70, 70 billion pounds. So more money, definitely an improvement on the last spending review, which talked about, you know, sending one of our, which was in 2021 before the, before the Russian invasion of Ukraine, talking about, you know leaning into aircraft carriers and you know one of the outputs of the review being oh we should send our aircraft carrier on a big tour of the and you know Indo-Pacific you know so I think people about now focus more rightly on technology in the future and I think we are moving away before we used to focus on like big what we would probably call white elephants now like big you know aircraft carrier investments and you know slightly kind of show off type show type things like that, but not have the money to do it properly.

33:56So you would, for example, spend 6 billion on two aircraft carriers, but you wouldn't have the number of F-35s to even make those operational, right? So I think the focus has gone away from vanity projects like that now to more AI, cyber, autonomous systems, et cetera. My personal sake is it's not enough. No, but as you also talked about before, a lot of this amount goes on very boring logistical infrastructural stuff it goes yeah one and a half billion into upgrading barracks and and and you know the places where the squaddies sleep it's also yeah yeah yeah but it's the same when you talk about the 200 billion health budget like actually a relatively small amount goes on technology most of it goes on you know people and infrastructure etc and i think mads mads pointed out last time that the germans have you know failed to find the you know the details of their reservists so all the money goes into like figuring out these problems of identifying people and calling up people and coming up with recruitment programs.

34:52I mean, logistics is an absolutely critical part of defense, obviously. So you can't not invest in that. So let's take it back to startups. There is a 400 million, which seems very small, defense innovation fund that they've announced. That I think is an annual amount. They want to actually start getting that out the door from May to July onwards. So actually being relatively quick. So yes, it's a relatively small amount. It's something it will, some of that will trickle through to startups. Of course, the existing defense primes and contractors have a massive, massive, massive head start and they already have the procurement systems in place.

35:28So I think this kind of slightly guilt-edged, optimistic view that lots of defense startups are going to be running around with big, shiny contracts might be a little bit optimistic. But there certainly is opportunities for them. I think they are going to need to learn some smarts on the procurement and distribution side, and that will take probably longer than you would hope. So the backdrop here is still lots more money going into tech. You know, this is a week in which Anduril has just announced a two and a half billion fundraiser, the 31 billion valuation founders funds put one billion into that round.

35:59Right. So there's still lots and lots of money going going into this. Interestingly, in that strategic defense report of the UK last week, they referred to a new prime. You know, that's the language they use. So there is an acknowledgement that both the future does envisage not just the classic BAE systems, Lockheed Martin, et cetera, winning all of the contracts. So I think this is a good thing. We've seen, and we talked about it last week, the SAFE, not the SAFE investment instrument, but the security action for Europe, which is 150 billion initiative in the EU, which has similar goals. So this is all part of upskilling, uptooling, and there will be pickings, hopefully more than pickings, interesting things for technology startups working on drones, automation, AI, cyber.

36:48and we're seeing you know if you just look at the news just picking out you know recent rounds for example there's a company called labris that just raised a 20 million series a in the uk led by plural and albion company called lend your ai in estonia that just raised 6 million seed to focus on autonomy stacks for drones to enable them to operate in gps denied environments so when you look at what we do on our daily basis and you guys are obviously a sas fund i'm a little bit more deep tech in my investments. But if you look at the kind of investments that we've been looking at over the last five to six years, now you're seeing more and more defense companies woven into the pipeline and deal flow and what founders are building.

37:27So I think that's fascinating. And they're not all guns companies. They are, you know, Labris is a workforce management company. So in defense, a lot will be focused on that kind of logistical piece. so big picture all good lots to be done long term these are kind of targets that that will take time to hit and money trickling through to seed stage startups just just takes time especially in a government procurement process my personal take is that this is going to lift europe this this spend and this focus will lift europe financially i think it'll have some serious inroads but mads Do you agree or where would you take this topic?

38:08I just kind of thought going through my head. So you're positive in that defense review is kind of, you know, spending on UK defense innovation. There's this new 400 million pound ring fence fund targeting startups. And it sounds like a wonderful thing. And then you put it in the context of, as you've just said, Lomax and Dural Racing, two and a half billion dollars, which is six times the entire innovation budget of the UK in this defense review. Are we wasting our time here? Okay. One thing I will say, Matt, sorry, is that you're not wrong. But given this move to - I'm just asking the question.

38:53No, no. Given this - No, no. Fine, fine, fine. Clearly, when we were just at the beginning of this pod talking about the difference, in quantum in amounts across many things when comparing UK, Europe to the US. But actually, defense is interesting because it's an area where even well-funded companies like Enduro may struggle to get traction given the move towards defensive sovereignty. So actually, in a way, the UK and the European startups for once actually have a bit of a head start or at least have a major competitive threat removed. I mean, if you look at Palantir that is just on the data side that has won hundreds, certainly tens, if not hundreds, and billions of government contracts in Europe for what it does, right?

39:39I don't think Andruil might struggle to do the same in defense. And so actually there is scope for the Helsings of this world, being the sort of equivalent of Andruil in Europe. These are not insignificant amounts of money in the context of startup. You know, talked about if you want an IPO company these days, you need to be generating 250 to 300 million of revenue. There are businesses that can be built of this size with these budgets, I'm sure, in the UK and Europe. And they don't have the U.S. competitive threat. Another vector, another angle, let's accept everything you've said. The U.S. is not the main competitive threat here, is it?

40:18I mean, the main competitive threat is China. And even if you feel that China invading Europe is a bit far-fledged, which it probably is, we know that they have a close collaboration with the Russians. The Russians want to export oil and minerals. And in return, they'd like to buy Chinese technology and arms. Are we wasting our time? You look at the amount of funding that's going into this sector in China. I mean, is this going to make any difference? I don't think we're wasting our time because you have to spend the money here. you have to have sovereign capability. It's like, I think we've learned, you know, in the last year, if we didn't already know.

40:54I'm talking about the scale. I'm talking about 400 million in what seems to be a global arms race with much, much bigger numbers. And talk about the whole context of a standalone UK defense review. And part of me is always, almost sort of saying, why are we even bothering? Is there any way to make a meaningful difference here? You bring up Helsing. That is probably one of the few really meaningful things happening in Europe right now. And it's not a UK company. So certainly there needs to be, I think UK and EU need to work together on this. UK is now trying to get into this whole safe concept that I just talked about, the security action for Europe.

41:36So I think that probably needs to be a pooled resource. By the way, sorry, the 400 million is the Defense Innovation Fund. there is billions going into you know cyber drones autonomous systems on top of that right so i think like there is 400 million of the 67 billion budget is not just going to technology it is a bigger proportion of that right but still i know i know what you mean i want to just lean into an adjacent topic around ai infrastructure because i think there is there is a segue here and i want to talk about this before we go ai infrastructure in europe we've talked about this a lot and andrew who's not with us today, this would be music in his ears.

42:14There is a consortium coming together to bid for one of these first new EU sponsored AI super factories in Europe. So I want to quickly delve into this and see if there is a connective line between defence and kind of this kind of economic growth piece. And can Europe do AI infrastructure? So Mads, can you lead us on this one we can talk about what's happening around these du ai super factories where we have seen a target of investing 20 billion into creating large-scale ai capability and we compare that to the u.s project stargate which is 100 to 500 billion in scope 100 billion to start up with So the first obvious observation is there's just a scale difference here once again.

43:04But I would say we are starting to see some real things happening on the ground. We've got one of the first consortia coming together. Deutsche Telekom is working together with SAP and others to get the first data center off the ground. So kind of first 100 ,000 GPU supercluster in Germany. It's a good thing. so there's signs that something is happening but gosh we need so much more so much faster hello max where would you take this one can we can the you can europe do ai infrastructure it can do yeah for sure and it just it will take time and capital and you know the energy you know energy costs are a major major stumbling block here and and so especially if if you if If you project that the power taken up or power usage of data centers is going to grow from low single digit percent to potentially up to a third of drawing electricity installed base in Europe and the US, for example, you've got to get those costs down.

44:08So this goes into the nuclear, like long term, preferably clean power that is delivered at affordable prices. I think depending on what stats you take, commercial energy in the US is anywhere from two to four times cheaper than the UK and Europe. So I think that has got to be a big thing to focus on. And I think the other thing, actually, if you look at the absolute numbers in terms of the number of data centers in the US, I think, is 5 ,000 in Europe. It's a lot, lot smaller, right? But interestingly, the capacity, I think, is only roughly in the US, roughly twice what we have in Europe as at the moment.

44:49However, the pipeline in the US is staggering. So that's where Europe is being left behind. So I think what Mads, you know, what we talked about here is important because it's sort of playing part of European catching up. Where the US is making progress is the pipeline. And I'll just give you one anecdote, chatting to someone, you know, looking to build a big data center outside London. he at the last check couldn't get his grid connection until 2035 you know there are these kind of yeah exactly exactly very very like you know planning all this kind of stuff that we've talked about before needs to needs to be i don't say we need to rip up all planning laws i'm just saying for critical national infrastructure you need to have a fast track process very simple yeah So I guess we'll put this in the wait and see, watch and hope bucket.

45:41But hopefully we can see much more sovereign control, much more AI infrastructure in Europe. And it looks like at least there's something happening, which is great. So deals of the week, I think. By the way, I can keep going a bit. Can I talk about lipid biopsies very quickly? You don't have a whole piece on this. Yeah, no, let's do it. Let's do it. Because I know this is a topic close to your heart. So there's been a nicer NHS breakthrough this week, isn't there? well yeah so i think i think this is interesting because we've talked about before like using technology in the past it's been about using ai to bring down government costs so in this case the nhs is the first government system to it to roll out a you know new technology liquid biopsy to a certain subset of cancer patients in breast cancer and lung cancer i think it's fascinating because it's a it's an example of a few things at play that get banded around a lot that we i think are actually seeing now in real life right so this is an example of precision medicine which is something that you know a lot of people talk about but i think it's good to see it in the real world and it's an example of the nhs being very forward-thinking and using a new technology to actually drive better outcomes and reduce costs which is your holy grail just explain for those that don't know what liquid biopsy so liquid biopsy is a blood test that can identify fragments of dna in the blood or circulating tumor dna it's as always with these these Technology started out in a lab, ended up being brought out of the lab into the kind of real world setting, largely from Silicon Valley and actually Boston and venture backed funding.

47:08So in the last 20 years, it's a good example of venture capital doing something that is very meaningful and impactful. Why is this relevant? So it's a very versatile, flexible technology that can be used in the context of cancer, for example, which is the main kind of use case, as it were, for a number of ways. ways. So first it can be used to detect cancer in healthy patients like you two and me hopefully. So it can be used as a screening device. That is not what it's being used for here and that is much sort of longer term. But that could be in the same way that people have been doing MRI scans.

47:39We've talked about NECO and Ezra etc before. You can actually do a simple blood test to look for circulating DNA of tumors in your blood to give you an early warning signal as to whether you actually have cancer. In this case, it's another use case, which is where you can use the liquid biopsy. So the blood test to actually understand more about the tumor. And then you, once you know more about the tumor, you can then drive specific treatments to it. So traditionally, normally to biopsy a tumor, you need to go into the body and take it out. That means an operation, general anesthetic, surgery, et cetera.

48:13This can now be done with a simple blood draw from a nurse. So that's fascinating. So you can then drive the specific treatments to it. You can at the same time monitor by looking at the tumor DNA activity in the blood, you can look at whether the response to the treatment is going well or badly. So I think that's a really interesting, and that's what it's being used for here. So it's being used for lung and breast cancer patients. Instead of doing an invasive, expensive, time-consuming, painful physical biopsy, you can look at the blood to then see what the profile of the tumor looks like and then you can decide which drugs to use so and that that's the precision medicine element you're using specific information to drive a precise treatment schedule for that patient and you could also use rolling this out right so this is now across across these two cancers only right and i think so for example as i said if you're a lung cancer patient or breast cancer patient you wouldn't necessarily have to have the invasive biopsy you can use a liquid biopsy to to make decisions around your treatment plan you can also So use it to monitor, as I said, how you're reacting to the treatment.

49:13You can also then use it, which is the way that I'm using it in my own treatment, is to once you're in recurrence, whether it's coming back. So you keep doing blood draws to see whether actually the numbers spike up. Now, why is this interesting in the NHS? So this is actually only going to save in the context of lung cancer£11 million a year. So we talk about the NHS budget being£200 billion, whatever,£220 billion. And, you know, so in a way you'd be like, well, so frigging what? Like, but at the same time, that's just lung cancer. So if you roll that out across all solid tumor, solid tumors are roughly 80 to 85 % of cancers.

49:48You roll that across all cancer, you probably got savings of 250 to 500 million a year, right? So this is just an example of one technology being used to drive better patient outcomes, reduce costs potentially at the, say, 500 million mark. I think this is fascinating. The NHS is the first government to adopt this. And this is great news. you know and i love the fact that you've that you've lit up i love seeing your face like this is this is technology venture-backed tech coming good exactly solving in the uk and helping real world people do better things that's what a what a wonderful thing i mean the only thing i would say is all of the investment you know the billions that have gone into this you know sequoia of backed companies and they're all listed now garden notera etc all in the us however there are some very interesting startups in Europe now that are taking this technology and applying it not just to cancer you can use it to check whether transplants will be accepted you can use it potentially for outsiders there's a whole new kind of potential use case for this this technology so I you know I'm optimistic for the future on it lovely Mads anything you'd like to add here I think it's as you say it's a wonderful story you know providing some of the context around what's happening in healthcare in the UK is that we are in a pretty dire situation.

51:07We've got spending increased by 14 % since 2019, but outcomes are nearly 7 % down in terms of productivity, in terms of what we're getting for the money. And so we need technology like this to improve productivity, and we have technology. And that's the great news. I think there is a real political will to try and implement As I saw that there was£180 million put aside across six categories to put AI diagnostics already this year. We're moving in the right direction. But what I'm still missing is some courage around saying what this will mean. If you look over the horizon of this parliament, the next parliament, and the budgets and the fiscal outlooks, looks, when can we start to take resource that right now is going into not delivering very much and moving that to more productive areas?

52:02And what I worry is that what will happen is what often happens in public services is that we just keep spending and spending and spending more year after year instead of actually saying, gosh, we can do so much more now with less money. Doesn't that then mean we can free up some resource to put to some of all these other things we talked about around defense, around energy, around AI in general. That's what I would love to see. Yeah. What you don't want is to say the 500 million of savings that this could potentially save across all of oncology to be just like absorbed by some bureaucratic land and thing elsewhere in the NHS.

52:42Exactly. Yeah. Gents, before we scooch off, anyone got any deals of the week? Lomax got anything on your docket? Two deals of the week. So Mubi, which is a 2007 initiated startup in effectively streaming, but they've also moved into production. So maybe you could kind of call it a sort of London-based Netflix. Maybe it's been historically focused more on artistic and independent films. It has just raised, out of nowhere,$100 million from Sequoia. So good for them. Again, building a big company takes a long, long time. and you don't need to, you know, get to 10, getting to 10, 8, 10 million of ARR in 10 minutes, which it seems to be the sort of vogue these days is, is there are other ways to do it.

53:25So, so good for them. And I think actually just talking about health, so psychedelics is a big merger that was announced this week in psychedelics. So we're actually Europe does have some of the biggest players in the world. So it does actually have a kind of prominent position. I'm psychedelics being relevant because they are trying to come up with better treatments for mental health, which is one of the biggest components of these health budgets that we just talked about, right? So ATI Life Sciences has announced its effectively acquisition or merger with Beckley SciTech. Why is that interesting?

53:56It's consolidation in the industry. It's an exit event for ATI as a listed company. So it's an exit event for Beckley, which is now waiting the readout of a phase two clinical trial, applying a naturally occurring substance called DMT, which is found in certain plants in South America and frogs. So the frog licking kind of. Isn't this the ayahuasca stuff? No, no, no, no, no, no, no, no, no. Very, very different. But I was connected for sure, but this has nothing to do with ayahuasca ceremonies. This is like DMT delivered in a very like clinical setting. There are, they, this has been, um, run a clinical trial for, um, treatment resistant depression so trd so if if there's a positive readout um that will be great for everyone and psychedelics now is awaiting two to three very very important big clinical trials so you probably read about lots of money going into this very hot area it's now kind of got to the next plateau and then we'll see now the effects or the conclusions of those clinical trials and then you see whether the FDA and the MA in Europe will actually approve these things.

55:06And it looks like with Kennedy and Trump in the White House, they are actually sympathetic towards this. So let's see. Mads, any deals of the week from you, Moen? We occasionally talk about European founders and startups going to the US to raise capital. So there's a story here, which is maybe both a bit of that, but maybe also sort of like silver lining on something else, which is Grammarly raising a billion dollars. And it's a Ukrainian born company. And they raised a billion dollars in a round led by General Catalyst. It's wonderful to see some amazing tech coming out of Ukraine of all places.

55:48And as far as I understand, they still have a fair deal of devs and techs sitting over there in the context of all the terrible things that are going on in that country. So I think there's some positivity here, although I would have loved to see that route being underwritten by a London-based firm and not a US firm. GC, what a beast. And also, I think interesting, also in the context of what we talked about in this pod before, that was a non-dilutive financing, right? So that was a 1 billion financing. And they're going to take, I think, rev share off the top of what they're going to use the 1 billion for with the new products and services, et cetera, that they build.

56:23they'll be taking a rev share of that to pay obviously with interest and coupon on the 1 billion so it's an example of GC one of the being the big behemoths of these venture funds innovating on the sort of financial models that they offer to startups and also offer to their LPs I so want to talk about new VC funding models at some point at some point Mads is least favorite top mate but i think i know i so want to go there i so want to go there i'm going to keep nagging and nagging um jen's wasn't very one billion so just just let me just think about it though if you you know you're the founder of grammarly you've just raised one billion in non-dilutive funding i mean that's pretty pretty damn good no yeah i'd take that every day of the week well i take it it's an early stage vc early stage vc when one of your companies does that it's phenomenal no yeah good for gc gents it is a pleasure and a gift as always talking to you i'll catch you next week bye

57:27tear down this wall it's more than just an ally this is a union of values let's start acting

From the publisher

Welcome to a new episode of the

EUVC podcast

, where

and

of

and

from

gather to unpack the macro forces and micro signals shaping European tech and venture.

This week, the trio dive into:

  • Why Europe’s fiscal firepower could be its unfair advantage
  • The growing exodus of IPOs from the UK to the US
  • Strategic defense investment—can the UK move the needle?
  • How AI and capital markets are colliding
  • And yes, we close on psychedelics and patient-first biotech breakthroughs


Here's what’s covered:

02:15 Europe’s Fiscal Advantage: Why Better Balance Sheets Matter for Innovation

07:00 The Return of Low Rates: What It Means for Startups

11:20 London vs. New York: The IPO Drain

17:00 Why Capital Leaves: Liquidity, Coverage & the Search for Growth

21:30 Rebuilding the UK Market: The Case for LP Allocation Reform

25:50 Beyond IPOs: The Full-Stack Capital Problem

30:40 AI and Lawsuits: Welcome to the New Frontier

33:10 Defense Tech Heats Up: Drones, AI & Strategic Capital

38:40 Can the UK Compete? Global Arms Races & National Reviews

42:30 Liquid Biopsies & Healthcare Breakthroughs

46:20 NHS Efficiency Crisis: More Money, Worse Outcomes

50:30 Psychedelics on the Edge: Awaiting the Data Drop

More from EUVC

All 626 episodes
E488 | This Week in European Tech with Dan, Mads & LomaxEUVC · 58 min
Listen in VO